نتائج البحث - "Daniela Bartoletti"

1

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis

المصدر: Cancer. 128:2449-2454

مصطلحات موضوعية: myelofibrosis, outcome, peripheral blasts, response, ruxolitinib, Cancer Research, Pyrimidines, Treatment Outcome, Oncology, Primary Myelofibrosis, Nitriles, Humans, Pyrazoles

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333c2888f3447b35fd31fffe8e8c4addTest
https://doi.org/10.1002/cncr.34216Test

2

Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study

المساهمون: Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F

مصطلحات موضوعية: ruxolitinib, myelofibrosis, Hematology, Iron Chelating Agents, Benzoates, cancer, deferasirox, iron overload, Pyrimidines, myelofibrosi, MED/15 - MALATTIE DEL SANGUE, Primary Myelofibrosis, Nitriles, Humans, Pyrazoles, Retrospective Studies

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c156776f50e229cb57d6b834ba5609bTest
http://hdl.handle.net/20.500.11769/522099Test

3

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

المساهمون: Massimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, Giuseppe A. Palumbo, Nicola Polverelli, Elisabetta Abruzzese, Micaela Bergamaschi, Alessia Tieghi, Mario Tiribelli, Alessandra Iurlo, Francesco Cavazzini, Nicola Sgherza, Gianni Binotto, Alessandro Isidori, Mariella D’Adda, Monica Crugnola, Costanza Bosi, Florian Heidel, Matteo Molica, Luigi Scaffidi, Daniele Cattaneo, Roberto Latagliata, Giuseppe Auteri, Roberto M. Lemoli, Renato Fanin, Domenico Russo, Franco Aversa, Antonio Cuneo, Gianpietro Semenzato, Lucia Catani, Michele Cavo, Nicola Vianelli, Robin Foà, Francesca Palandri

المصدر: Annals of Hematology. 98:889-896

مصطلحات موضوعية: Male, Ruxolitinib, Time Factors, Myelofibrosis, BMI, CCI, Comorbidities, Adult, Age Factors, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Middle Aged, Primary Myelofibrosis, Pyrazoles, Sex, Sex Factors, Survival Rate, Body Mass Index, Gastroenterology, 0302 clinical medicine, 80 and over, Hematology, Myelofibrosi, General Medicine, 030220 oncology & carcinogenesis, Cohort, BMI, CCI, Comorbidities, Myelofibrosis, Ruxolitinib, Comorbiditie, Underweight, medicine.symptom, medicine.drug, medicine.medical_specialty, Anemia, NO, 03 medical and health sciences, Internal medicine, Nitriles, medicine, Survival rate, business.industry, medicine.disease, Pyrimidines, business, Body mass index, 030215 immunology

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d64ab7637eb4c5a380b91b3340934c2Test
https://doi.org/10.1007/s00277-018-3569-1Test

4

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity

المؤلفون: Giuseppe Auteri, Daniela Bartoletti, Christian Di Pietro, Emanuele Sutto, Camilla Mazzoni, Andrea Davide Romagnoli, Nicola Vianelli, Tiziana Lazzarotto, Michele Cavo, Francesca Palandri

المصدر: Leukemia Research. 116:106819

مصطلحات موضوعية: Cancer Research, COVID-19 Vaccines, Pyrimidines, Oncology, SARS-CoV-2, Nitriles, COVID-19, Humans, Pyrazoles, Hematology, Severity of Illness Index

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6326af6c7fadf63259eabe9c6163ddd2Test
https://doi.org/10.1016/j.leukres.2022.106819Test

5

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

المساهمون: Palandri F., Tiribelli M., Breccia M., Bartoletti D., Elli E.M., Benevolo G., Martino B., Cavazzini F., Tieghi A., Iurlo A., Abruzzese E., Pugliese N., Binotto G., Caocci G., Auteri G., Cattaneo D., Trawinska M.M., Stella R., Scaffidi L., Polverelli N., Micucci G., Masselli E., Crugnola M., Bosi C., Heidel F.H., Latagliata R., Pane F., Cuneo A., Krampera M., Semenzato G., Lemoli R.M., Cavo M., Vianelli N., Bonifacio M., Palumbo G.A.

المصدر: CancerReferences. 127(15)

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad9fa181c09a6df953c64f23aee767c3Test
https://pubmed.ncbi.nlm.nih.gov/33794557Test

6

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

المساهمون: Palandri F., Palumbo G.A., Elli E.M., Polverelli N., Benevolo G., Martino B., Abruzzese E., Tiribelli M., Tieghi A., Latagliata R., Cavazzini F., Bergamaschi M., Binotto G., Crugnola M., Isidori A., Caocci G., Heidel F., Pugliese N., Bosi C., Bartoletti D., Auteri G., Cattaneo D., Scaffidi L., Trawinska M.M., Stella R., Ciantia F., Pane F., Cuneo A., Krampera M., Semenzato G., Lemoli R.M., Iurlo A., Vianelli N., Cavo M., Breccia M., Bonifacio M.

المصدر: Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-4 (2021)

مصطلحات موضوعية: Ruxolitinib, medicine.medical_specialty, Humans, Janus Kinases, Multivariate Analysis, Primary Myelofibrosis, Protein Kinase Inhibitors, Pyrazoles, Risk Factors, Treatment Outcome, medicine.medical_treatment, Splenectomy, lcsh:RC254-282, Nitriles, Pyrimidines, Ruxolitinib discontinuation syndrome, risk factors, myelofibrosis, NO, Myeloproliferative disease, Internal medicine, Correspondence, medicine, Risk factor, Bone pain, Myelofibrosis, Respiratory distress, business.industry, Incidence (epidemiology), Hematology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Discontinuation, Oncology, medicine.symptom, business, Haematological diseases, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a62daabaefd684de2397c145f15acefTest
https://pubmed.ncbi.nlm.nih.gov/33414394Test

7

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

المساهمون: Palandri F., Breccia M., Tiribelli M., Bonifacio M., Benevolo G., Iurlo A., Elli E.M., Binotto G., Tieghi A., Polverelli N., Martino B., Abruzzese E., Bergamaschi M., Heidel F.H., Cavazzini F., Crugnola M., Bosi C., Isidori A., Auteri G., Forte D., Latagliata R., Griguolo D., Cattaneo D., Trawinska M., Bartoletti D., Krampera M., Semenzato G., Lemoli R.M., Cuneo A., Di Raimondo F., Vianelli N., Cavo M., Palumbo G.A.

مصطلحات موضوعية: Male, Cancer Research, Ruxolitinib, ruxolitinib, Gastroenterology, 0302 clinical medicine, myelofibrosi, 80 and over, risk factors, blast phase, myelofibrosis, outcome, Adult, Aged, Aged, 80 and over, Blast Crisis, Disease Progression, Female, Follow-Up Studies, Humans, Janus Kinases, Middle Aged, Primary Myelofibrosis, Prognosis, Pyrazoles, Retrospective Studies, Survival Rate, Young Adult, Incidence (epidemiology), Hematology, General Medicine, risk factor, Oncology, 030220 oncology & carcinogenesis, blast phase, myelofibrosis, outcome, risk factors, ruxolitinib, Blast Crisis, Disease Progression, medicine.drug, medicine.medical_specialty, Socio-culturale, Alpha interferon, 03 medical and health sciences, Internal medicine, Nitriles, medicine, Risk factor, Myelofibrosis, Survival rate, business.industry, Induction chemotherapy, Anagrelide, medicine.disease, Pyrimidines, business, 030215 immunology

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3107b0f9e218bf3762022ccfd3737a6Test
https://hdl.handle.net/11379/569845Test

8

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

المؤلفون: Elena Maria Elli, Florian H. Heidel, Uros Markovic, Fabrizio Pane, Gianpietro Semenzato, Daniela Bartoletti, Francesca Palandri, Giulia Benevolo, Mauro Krampera, Malgorzata Monika Trawinska, Micaela Bergamaschi, Mario Tiribelli, Giovanni Caocci, Lucia Catani, Elisabetta Abruzzese, Massimo Breccia, Rossella Stella, Antonio Cuneo, Fabio D'Amore, Alessandro Isidori, Costanza Bosi, Monica Crugnola, Lisa Gandolfi, Domenico Russo, Alessandra Iurlo, Nicola Polverelli, Roberto M. Lemoli, Michele Cavo, Gianni Binotto, Roberto Latagliata, Francesco Cavazzini, Bruno Martino, Daniele Cattaneo, Nicola Vianelli, Novella Pugliese, Luigi Scaffidi, Massimiliano Bonifacio, Mariella D'Adda, Alessia Tieghi, Giuseppe Auteri, Giuseppe A. Palumbo

المساهمون: Polverelli N., Elli E.M., Abruzzese E., Palumbo G.A., Benevolo G., Tiribelli M., Bonifacio M., Tieghi A., Caocci G., D'Adda M., Bergamaschi M., Binotto G., Heidel F.H., Cavazzini F., Crugnola M., Pugliese N., Bosi C., Isidori A., Bartoletti D., Auteri G., Latagliata R., Gandolfi L., Martino B., Scaffidi L., Cattaneo D., D'Amore F., Trawinska M.M., Stella R., Markovic U., Catani L., Pane F., Cuneo A., Krampera M., Semenzato G., Lemoli R.M., Vianelli N., Breccia M., Russo D., Cavo M., Iurlo A., Palandri F.

مصطلحات موضوعية: Male, Ruxolitinib, Skin Neoplasms, Lymphoma, ruxolitinib, Aggressive lymphoma, Gastroenterology, Hydroxycarbamide, 0302 clinical medicine, myelofibrosi, Risk Factors, Neoplasms, 80 and over, Aged, 80 and over, Thrombocytosis, Incidence (epidemiology), Incidence, Hazard ratio, Neoplasms, Second Primary, Hematology, Arteries, Middle Aged, Second Primary, JAK inhibitor, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Context (language use), myelofibrosis, JAK inhibitors, second cancer, toxicity, NO, 03 medical and health sciences, Internal medicine, Nitriles, medicine, Humans, Janus Kinase Inhibitors, Myelofibrosis, Aged, Retrospective Studies, business.industry, Thrombosis, medicine.disease, Case-Control Studies, Follow-Up Studies, Multivariate Analysis, Primary Myelofibrosis, Pyrazoles, Pyrimidines, business, 030215 immunology

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d8abbcaca804c8d9620fa8227a1112fTest
http://hdl.handle.net/11562/1033116Test

9

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

المساهمون: Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, Giulia Benevolo, Florian Heidel, Giuseppe A. Palumbo, Monica Crugnola, Elisabetta Abruzzese, Daniela Bartoletti, Nicola Polverelli, Micaela Bergamaschi, Mario Tiribelli, Alessandra Iurlo, Massimo Breccia, Francesco Cavazzini, Alessia Tieghi, Gianni Binotto, Alessandro Isidori, Bruno Martino, Mariella D'Adda, Costanza Bosi, Elena Sabattini, Umberto Vitolo, Franco Aversa, Adalberto Ibatici, Roberto M. Lemoli, Nicola Sgherza, Antonio Cuneo, Giovanni Martinelli, Giampietro Semenzato, Michele Cavo, Nicola Vianelli, Maria R. Sapienza, Roberto Latagliata

المصدر: British journal of haematology. 183(1)

مصطلحات موضوعية: 0301 basic medicine, elderly, high molecular risk, high molecular risk mutations, myelofibrosis, ruxolitinib, Ruxolitinib, medicine.medical_specialty, Genotype, Socio-culturale, Hematology, Older population, 03 medical and health sciences, 0302 clinical medicine, myelofibrosi, Older patients, Risk Factors, Internal medicine, Nitriles, Medicine, Humans, Myelofibrosis, Aged, Janus Kinases, Retrospective Studies, business.industry, Age Factors, elderly, high molecular risk, high molecular risk mutations, myelofibrosis, ruxolitinib, medicine.disease, Mutation, Primary Myelofibrosis, Pyrazoles, Survival Analysis, Treatment Outcome, Peripheral blood, Discontinuation, 030104 developmental biology, Pyrimidines, 030220 oncology & carcinogenesis, high molecular risk mutation, business, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fcba8eb0dec4f4376af60ab94b819dTest
https://pubmed.ncbi.nlm.nih.gov/30010187Test

10

Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis

المؤلفون: Lucia Catani, Nicola Vianelli, Francesca Palandri, Daria Sollazzo, Emanuela Ottaviani, Marco Romano, Martina Barone, Daniela Bartoletti, Dorian Forte, Michele Cavo, Pier Luigi Tazzari, Giuseppe Auteri, Francesca Ricci, Maria Letizia Bacchi Reggiani

المساهمون: Barone M., Ricci F., Sollazzo D., Ottaviani E., Romano M., Auteri G., Bartoletti D., Reggiani M.L.B., Vianelli N., Tazzari P.L., Cavo M., Forte D., Palandri F., Catani L., Bartoletti, Daniela [0000-0003-2036-2896], Catani, Lucia [0000-0002-4650-201X], Apollo - University of Cambridge Repository

وصف الملف: STAMPA; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71094d37e5786b8f561fec6b6f5bab2fTest

تنقيح النتائج